Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily and twice daily in the treatment of bilateral nasal polyposis: A placebo-controlled randomized study in adult patients

Clinical and Experimental Allergy

Volumn 30, Issue 1, 2000, Pages 94-102

  Penttila M ^a   Poulsen, P ^d   Hollingworth, K ^b   Holmstrom M ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b GLAXOSMITHKLINE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Glaxo Wellcome Res and Development ^*

Author keywords

Fluticasone propionate; Nasal corticosteroid; Nasal drops; Nasal polyposis

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; NOSE DROPS; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EPISTAXIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; NOSE OBSTRUCTION; NOSE POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS;

EID: 0033961604     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2000.00695.x     Document Type: Article

References (34)

1. 1 Hosemann W, Gode U, Wagner W. Epidemiology, pathophysiology of nasal polyposis, and spectrum of endonasal sinus surgery. Am J Otolaryngol 1994; 15:85-98.
2. 2 Settipane GA. Nasal polyps and immunoglobulin E (IgE). Allergy Asthma Proc 1996; 17:269-73.
3. 3 Sin A, Terzioglu E, Kokuludag A et al. Allergy as an etiologic factor in nasal polyposis. J Invest Allergy Clin Immunol 1997; 7:234-7.
4. 4 Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. J Allergy Clin Immunol 1977; 59:17-21.
5. 5 Drake-Lee A, McLaughlan P. Clinical symptoms, free histamine and IgE in patients with nasal polyps. Int Arch Allergy Appl Immunol 1982; 69:268-71.
6. 6 Stierna PLE. Nasal polyps: relationship to infection and inflammation. Allergy Asthma Proc 1996; 17:251-7.
7. 7 Bernstein B, Gorfien J, Noble B. Role of allergy in nasal polyposis. A review. Otolaryngol Head Neck Surg 1995; 113:724-32.
8. 8 Rowe-Jones JM, Mackay IS. Management of nasal polyps. Current Opin Otolaryngol Head Neck Surg 1998; 6:41-6.
9. 9 Lund VJ. Diagnosis and treatment of nasal polyps. Br Med J 1995; 311:1411-4.
10. 10 Lildholdt T. Position statement on nasal polyps. Rhinology 1994; 32:126.
11. 11 Holmberg K, Juliusson S, Balder B, Smith DL, Richards DH, Karlsson G. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 1997; 78:270-6.
12. 12 Lund VJ, Flood J, Sykes AP, Richards DH. The effect of fluticasone propionate in severe polyposis. Arch Otolaryngol Head Neck Surg 1998; 124:513-8.
13. 13 Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol 1995; 20:26-30.
14. 14 Johansen LV, Illum P, Kristensen S, Winther L, Petersen SV, Synnerstad B. The effect of budesonide (Rhinocort®) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol 1993; 18:524-7.
15. 15 Ruhno J, Andersson B, Denburg J et al. A double-blind comparison of intranasal budesonide with placebo for nasal polyposis. J Allergy Clin Immunol 1990; 86:946-53.
16. 16 Chalton R, Mackay I. Double blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis. Br Med J 1985; 291:788.
17. 17 McDowall JE, Mackie AE, Ventresca GP, Bye A. The human pharmacokinetics and bioavailability of intranasal fluticasone propionate. Clin Drug Invest 1997; 14:44-52.
18. 18 Wiseman LR, Benfield P. Intranasal fluticasone propionate. A reappraisal of its pharmacological and clinical efficacy in the treatment of rhinitis. Drugs 1997; 53:885-907.
19. 19 Meltzer EO, Orgel HA, Bronsky EA et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990; 86:221-30.
20. 20 Nathan RA, Bronsky EA, Fireman P et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991; 67:332-8.
21. 21 Scadding GK, Lund VJ, Jacques A, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic rhinitis. Clin Exp Allergy 1995; 25:737-43.
22. 22 Hardy JG, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol 1985; 37:294-7.
23. 23 Harris AS, Nilsson IM, Wagner ZG, Alkner U. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. J Pharm Sci 1986; 75:1085-8.
24. 24 Drake-Lee AB. Nasal Polyps. In: MacKay I, ed. Rhinitis: Mechanisms and Management. London: Royal Society of Medicine Services Ltd, 1989:141-52.
25. 25 Daley-Yates PT, McAllister T. Systemic bioavailability of fluticasone propionate administered as nasal drops (FP-Drops) and aqueous nasal spray formulations (FPANS). Allergy 1998; 53 (Suppl. 43):158.
26. 26 Flynn MD, Beasley P, Tooke JE. Adrenal suppression with intranasal betamethasone drops. J Laryngol Otol 1992; 106:827-8.
27. 27 Gallagher G, Mackay I. Doctors and drops. Br Med J 1991; 303:761.
28. 28 Mackay IS. Topical medical management of allergic conditions of the nose. Part 2: Intranasal steroids. In: Mackay IS, ed. Rhinitis: Mechanisms and Management. London: Royal Society of Medicine Services Ltd, 1989:183-98.
29. 29 Cain WS, Rabin D. Comparability of two tests of olfactory functioning. Chem Senses 1989; 14:479-85.
30. 30 Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardised microencapsulated test of olfactory function. Physiol Behav 1984; 32:489-502.
31. 31 Youlten LJF. The peak nasal inspiratory flow meter: a new instrument for the assessment of the response to immunotherapy in seasonal allergic rhinitis. Allergol Immunopathol 1980; 8:344.
32. 32 Mygind N, Lildholdt T. Nasal polyps treatment: medical management. Allergy Asthma Proc 1996; 17:275-82.
33. 33 Mullol J, Xaubet A, López E, Roca-Ferrer J, Picado C. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 1995; 50:270-4.
34. 34 Lund VJ, Aaronson D, Bousquet J et al. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49:1-34.